medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2013, Number 4

<< Back Next >>

Rev Esp Med Quir 2013; 18 (4)

Expression of Gen Bcl2 in Prostate Cancer Resistant to Castration. Urologic Perspective

Velázquez MRF

Language: Spanish
References: 41
Page: 339-344
PDF size: 297.12 Kb.


ABSTRACT

Prostate cancer is a frequent disease in the Mexican population, the castration resistant variety causes high morbidity/ mortality rates. The Bcl-2 family members induce and inhibit the apoptosis process. There is evidence that these members are active in prostate cancer patients. Because of this, the role of Bcl-2 in castration resistant prostate cancer is investigated. To establish the Bcl-2 role in castration resistant prostate cancer a non-extensively reviews in national and international electronic browsers were made. 41 papers were included. The castration resistant prostate cancer can appear during the next five years in 10-20%. Bcl-2 is present in localized prostate cancer, both with progression or not progression after primary treatment. There was no evidence of Bcl2 activity in advanced prostate cancer with or without castration resistant. Bcl2 is present in localized prostate cancer with or without subsequent disease progression. The presence of Bcl2 in castration resistant prostate cancer was not informed.


REFERENCES

  1. Organización Mundial de la Salud. [OMS] (2010). Cáncer. Disponible en: http://www.who.int/mediacentre/factsheets/ fs297/es/index.html

  2. León G, Cabrera D, De la Rosa B. Cáncer de próstata en México: su registro en las estadísticas. Epidemiología 2009;26:1-2.

  3. Instituto Nacional de Estadística y Geografía (INEGI). Estadísticas a Propósito del Día Mundial contra el Cáncer. México, DF, 4 de febrero de 2010.

  4. Instituto Nacional de Estadística y Geografía (INEGI). Serie de Estadísticas Vitales. 2008:1-6.

  5. Bernal L. Epidemiología del cáncer de próstata. Rev Oncol 2001;5:11-21.

  6. Merayo Ch, Sánchez G, Santana Z, Pérez R y col. Prevalencia del cáncer de próstata incidental en el Hospital General Dr. Manuel Gea González; 20 años de revisión. Rev Mex Urol 2009;69:147-152.

  7. Jiménez RMA, Solares SM, Martínez CP, Aguilar PJL y col. Oncoguía: cáncer de próstata. Cancerología 2011;6:13-18.

  8. Márquez J, Rojas L, Ávila N, Pacheco C y col. El costo del cáncer de próstata. ¿Qué esperamos? Rev Mex Urol 2005;65:307-311.

  9. Vega R, Figueroa H. Evaluación del acetato de ciproterona en el control del cáncer de próstata avanzado (D-II). Bol Goleg Mex Urol 1996;13:77-82.

  10. Ricardez A, Rodríguez M, Ricardez A, Pámanes A y col. Hormonoterapia para el manejo de cáncer de próstata. Reporte preliminar. Rev Mex Urol 2001;61:184-192.

  11. Tombal B, Stainler A. Hormone therapy in the management of prostate cancer. Eur Urol Rev 2010;5:22-26.

  12. Goodin S, Rao K, DiPaola R. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002;7:360-370.

  13. Hotte S, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol 2010;17:73-79.

  14. Motte N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 2011;59:572-583.

  15. Kirby M, Hirst C, Crawford E. Characterizing the castrationresistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180-1192.

  16. García E, Velázquez-Macías R, Leiva A, Reyes O y col. Tratamiento del cáncer de próstata hormonoresistente con calcitriol en pacientes del Hospital Regional Lic. Adolfo López Mateos. Rev Mex Urol 2003;63:274-284.

  17. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 2005;4:38-44.

  18. Jan de Jong I, Eaton A, Bladou F. LHRH agonist in prostate cancer: Frequency of treatment, serum testosterone measurement and castrate level: Consensus opinion from a roundtable discussion. Curr Med Res Op 2007. http://www. cmrojournal.com.

  19. Rove KO, Debruyne FM, Djavan B, Gomella LG, et al. Role of testosterone in managing advanced prostate cancer. Urology 2012;80:754-762.

  20. Cózar JM, Solsona E, Morote J, Miñana B, et al. Recommendations on the management of controversies in advanced castrate-resistant prostate cancer. Actas Urol Esp 2012;36:569-577.

  21. Kasper S, Cookson MS. Mecanismos que conducen a la aparición de cáncer de próstata hormonoresistente. Urol Clin N Am 2006;33:201-210.

  22. Culing Z, Bartsch G. Androgen axis in prostate cancer. J Cel Biochem 2006;99:3737-3781.

  23. Bakhshi A, Jensen JP, Goldman P, Wright JJ, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:889-906.

  24. Graninger WB, Seto M, Boutain B, Goldman P, et al. Expression of Bcl-2 and Bcl-2-Ig. Fusion transcripts in normal and neoplastic cells. www.jci.org/articles/view/113235/files/pdf

  25. Reed JC. Proapoptotic multidomain Bcl2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006;13:1378-1386.

  26. Reed JC. Bcl-2–family proteins and hematologic malignancies: history and future prospects. Blood 2008;111:3322- 3330.

  27. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-163.

  28. Häcker G, Weber A. BH3-only proteins trigger cytochrome C release, but how? Arch Biochem Biophys 2007;462:150- 155.

  29. Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor super family. Nat Rev Cancer 2002;2:420-430.

  30. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337.

  31. Garber K. New apoptosis drugs face critical test. Nat Biotechnol 2005;23:409-411.

  32. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989-1000.

  33. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-1012.

  34. Hockenbery DM, Zutter M, Hickey W, Nahm M, et al. Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-6965.

  35. Liu AY, Corey E, Bladou F, Lange PH, et al. Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996;65:85-89.

  36. McDonnell T, Troncoso P, Brisbay S, Logothetis C, et al. Expression of the proto-oncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Research 1992;52:6940-6944.

  37. Revelos K, Petraki C, Gregorakis A, Scorilas A, et al. Immunohistochemical. Expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Research 2005;25:3123-3134.

  38. Park S, Sung W, Kim M. p16INK4a-PTEN, E-cadherin, Bcl- 2 and Ki-67 expression in prostate cancer: Its relationship with the metastatic potential and known prognostic factors. Korean J Pathol 2010;44:597-604.

  39. Baseskioglu B, Akdogan B, Baydar D, Ozen H. Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy? Indian J Urol 2010;26:206-212.

  40. Cho I, Chung S, Cho K, Kim J, et al. Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: An interim analysis. Cancer Res Treat 2010;42:157-162.

  41. Gleave M, Tolcher A, Miyake H, Nelson C, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-2898.




2020     |     www.medigraphic.com